Strategic Priorities

Our Focus

Sustainable organic revenue growth

1
  • Market leading technologies and products
  • Highest levels of technical and regulatory expertise
  • Deep, long-term customer relationships & contracts
  • Broad range of programmes and capabilities

Margin improvement

2
  • High margin drug delivery device business
  • Delivering continued margin improvement in Aesica
  • Good operational leverage

Investing in innovation

3
  • Well-established development programmes in both divisions
  • Developing our own product innovations while committed to investing in new patient, clinician and customer-driven treatments
  • Differentiated "one-stop" capability

Selective M&A and investments

4
  • Track record of successful acquisitions and integration
  • Strategy to access new geographic markets & complementary technologies
  • Clear criteria to generate sustainable long-term shareholder value